Switching the Immunogenicity of Peptide Assemblies Using Surface Properties.
Biomaterials created from supramolecular peptides, proteins, and their derivatives have been receiving increasing interest for both immunological applications, such as vaccines and immunotherapies, as well as ostensibly nonimmunological applications, such as therapeutic delivery or tissue engineering. However, simple rules for either maximizing immunogenicity or abolishing it have yet to be elucidated, even though immunogenicity is a prime consideration for the design of any supramolecular biomaterial intended for use in vivo. Here, we investigated a range of physicochemical properties of fibrillized peptide biomaterials, identifying negative surface charge as a means for completely abolishing antibody and T cell responses against them in mice, even when they display a competent epitope. The work was facilitated by the modularity of the materials, which enabled the generation of a set of co-assembled fibrillar peptide materials with broad ranges of surface properties. It was found that negative surface charge, provided via negatively charged amino acid residues, prevented T cell and antibody responses to antigen-carrying assemblies because it prevented uptake of the materials by antigen-presenting cells (APCs), which in turn prevented presentation of the epitope peptide in the APCs' major histocompatibility class II molecules. Conversely, positive surface charge augmented the uptake of fibrillized peptides by APCs. These findings suggest that some surface characteristics, such as extensive negative charge, should be avoided in vaccine design using supramolecular peptide assemblies. More importantly, it provides a strategy to switch off potentially problematic immunogenicity for using these materials in nonimmunological applications.
Biomedical Engineering Department, Duke University , Durham, North Carolina 27708, United States.|Department of Surgery, University of Chicago , Chicago, Illinois 60637, United States.
Yi
Y
Wen
Department of Surgery, University of Chicago , Chicago, Illinois 60637, United States.
Amelia
A
Waltman
Department of Surgery, University of Chicago , Chicago, Illinois 60637, United States.
Huifang
H
Han
Biomedical Engineering Department, Duke University , Durham, North Carolina 27708, United States.|Department of Surgery, University of Chicago , Chicago, Illinois 60637, United States.
Joel H
JH
Collier
biomaterial; immunogenicity; nanofiber; supramolecular; vaccine
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6728-33
10841570
Cancer Res. 2002 Dec 1;62(23):6831-6
12460895
Biomaterials. 2005 Jun;26(16):2991-9
15603794
Int J Pharm. 2005 Jul 25;298(2):315-22
15961266
Nat Biotechnol. 2007 Oct;25(10):1159-64
17873867
PLoS One. 2008 Jan 09;3(1):e1410
18183291
Nat Rev Drug Discov. 2008 Sep;7(9):771-82
18758474
Biomaterials. 2009 Apr;30(12):2400-10
19203790
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4623-8
19273853
Int J Pharm. 2009 Sep 8;379(1):41-50
19524654
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):622-7
20080728
Biomaterials. 2010 May;31(13):3657-66
20138662
J Control Release. 2010 Jul 14;145(2):102-8
20381556
Biochemistry. 2010 Aug 24;49(33):7108-18
20583779
Chem Soc Rev. 2010 Sep;39(9):3413-24
20603663
Nat Rev Drug Discov. 2010 Aug;9(8):615-27
20616808
Nat Rev Immunol. 2010 Nov;10(11):787-96
20948547
Nanoscale. 2011 May;3(5):2307-14
21499635
Biomacromolecules. 2011 Oct 10;12(10):3549-58
21863894
ACS Nano. 2012 Feb 28;6(2):1557-64
22273009
Adv Mater. 2012 Jul 24;24(28):3845-9
22550019
J Am Chem Soc. 2012 May 30;134(21):8730-3
22587010
Biomaterials. 2012 Sep;33(27):6476-84
22695068
Biomaterials. 2012 Dec;33(35):8907-16
22995710
Int J Nanomedicine. 2012;7:5577-91
23144561
Mol Pharm. 2013 Mar 4;10(3):1035-44
23419203
Adv Healthc Mater. 2013 Dec;2(12):1586-90
23616384
Biomaterials. 2013 Nov;34(34):8776-85
23953841
Nat Mater. 2013 Nov;12(11):978-90
24150416
Biomater Sci. 2013 Oct 1;1(10):null
24224082
Adv Mater. 2014 Mar 19;26(11):1642-59
24496667
Adv Healthc Mater. 2014 Aug;3(8):1217-21
24574174
Vaccine. 2014 May 30;32(26):3243-8
24736000
Adv Healthc Mater. 2014 Nov;3(11):1898-908
24923735
Nat Mater. 2014 Aug;13(8):829-36
24930032
Acta Biomater. 2014 Nov;10(11):4759-4767
25117952
AAPS J. 2015 Mar;17(2):380-8
25527256
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):488-93
25548169
Nanomedicine. 2015 Apr;11(3):633-44
25555350
Biomaterials. 2015 Jun;52:71-8
25818414
J Am Chem Soc. 2015 Apr 15;137(14):4823-30
25831137
Chem Rev. 2015 Oct 14;115(19):11109-46
26154342
Curr Opin Immunol. 2015 Aug;35:73-9
26163376
Biomater Sci. 2015 Feb;3(2):246-9
26218115
Biomacromolecules. 2015 Sep 14;16(9):2672-83
26225909
J Control Release. 2015 Dec 28;220(Pt A):141-148
26437263
Acta Biomater. 2016 Jan;30:62-71
26584836
Nanomedicine. 2016 Apr;12(3):677-687
26656533
ACS Nano. 2016 Jan 26;10(1):899-909
26700464
J Am Chem Soc. 2016 Mar 23;138(11):3813-23
26966844
J Control Release. 2016 May 28;230:1-12
27038493
J Biomed Mater Res A. 2016 Aug;104(8):1853-62
27129604